Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Operating Income Loss of -$20.20 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +34.4% in Operating Income Loss from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2019 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Operating Income Loss has declined by 13,120.9%.
- Historical annual values: Fiscal year 2025: -$20.20 million | Fiscal year 2024: -$30.80 million | Fiscal year 2023: -$39.50 million | Fiscal year 2022: -$28.23 million | Fiscal year 2021: -$10.10 million | Fiscal year 2021: -$10.10 million | Fiscal year 2020: -$2.43 million | Fiscal year 2020: -$724.7 thousand | Fiscal year 2019: -$376.9 thousand | Fiscal year 2019: -$152.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: